Ponatinib vs Imatinib in Frontline Philadelphia Chromosome–Positive Acute Lymphoblastic LeukemiaElias Jabbour, Josep‐María Ribera, Hagop M. Kantarjian et al.|JAMA|2024Cited by 119
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALLGregory W. Roloff, George Yaghmour, Ibrahim Aldoss et al.|Journal of Clinical Oncology|2024Cited by 36
Sociodemographic Factors Influencing Access to Chimeric Antigen T-Cell Receptor Therapy for Patients With Non-Hodgkin LymphomaSomya Khare, Eneida R. Nemecek, Staci Williamson et al.|Clinical Lymphoma Myeloma & Leukemia|2024Cited by 6
Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and AboveIbrahim N. Muhsen, Kristen M. O'Dwyer, Anjali S. Advani et al.|Blood|2024Cited by 3
NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free SurvivalYannis K. Valtis, Shabaz Malik, David Nemirovsky et al.|Blood|2024Cited by 3